We are analyzing https://link.springer.com/article/10.1007/s005200100292.

Title:
Bisphosphonates for cancer patients: why, how, and when? | Supportive Care in Cancer
Description:
Bisphosphonates (BPs) are potent inhibitors of osteoclast-mediated bone resorption, and it is well accepted that tumor cells in bone, especially breast cancer and myeloma cells, can stimulate osteoclast formation and activity leading to the release of growth factors or cytokines, which will further stimulate cancer cells
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Social Networks

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

bone, cancer, patients, article, bps, therapy, bisphosphonates, breast, data, pamidronate, metastatic, disease, privacy, cookies, content, care, infusions, information, publish, search, supportive, myeloma, clodronate, criteria, access, log, journal, research, published, body, mancini, potent, cells, rate, chemotherapy, administration, oral, skeletal, trials, lytic, results, obtained, viewed, potential, infusion, metastases, chapter, discover, springer, function,

Topics {✒️}

month download article/chapter monthly 6-mg infusions osteoclast-mediated bone resorption large-scale trials related subjects breast cancer metastatic metastatic breast cancer regular pamidronate infusions placebo infusions 15-min 4-mg infusion metastatic bone disease privacy choices/manage cookies article supportive care providing supportive care endocrinology/bone diseases breast cancer stimulate osteoclast formation review article published full article pdf metastatic bone pain lytic bone metastasis asco panel considered individual patient benefits aggressive osteolytic disease abnormal bone scan bone metastases european economic area scope submit manuscript longer lasting effect partial objective response plain radiographs normal classic antineoplastic drugs cost-effectiveness ratio institut jules bordet conditions privacy policy morbid skeletal events current therapeutic schemes recent data suggest objective response rate 30-min infusion accepting optional cookies pamidronate 90 mg conventional uicc criteria skeletal morbidity rate newer bp ibandronate bone resorption journal finder publish hormonal therapy adjuvant therapy check access

Questions {❓}

Bisphosphonates for cancer patients: why, how, and when?
Bisphosphonates for cancer patients: why, how, and when?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Bisphosphonates for cancer patients: why, how, and when?
         description:Bisphosphonates (BPs) are potent inhibitors of osteoclast-mediated bone resorption, and it is well accepted that tumor cells in bone, especially breast cancer and myeloma cells, can stimulate osteoclast formation and activity leading to the release of growth factors or cytokines, which will further stimulate cancer cells' growth and their secretion of osteolytic factors. BPs are now the standard treatment for cancer hypercalcemia, for which a dose of 90 mg of pamidronate or 1500 mg of clodronate is recommended; the former compound is more potent and has a longer lasting effect. Repeated pamidronate infusions exert clinically relevant analgesic effects in more than half of patients with metastatic bone pain. Recent data suggest that non-responding patients should perhaps be treated with higher doses. The optimal dose actually remains to be defined, especially as it is thought that it is probably a function of the disease stage. Regular pamidronate infusions can also achieve a partial objective response according to conventional UICC criteria and they can almost double the objective response rate to chemotherapy. Lifelong administration of oral clodronate to patients with breast cancer metastatic to bone reduces the frequency of morbid skeletal events by more than one-fourth. Two double-blind randomized placebo-controlled trials comparing monthly 90 mg pamidronate infusions to placebo infusions for 1–2 years in addition to hormone or chemotherapy in patients with at least one lytic bone metastasis have shown that the mean skeletal morbidity rate could be reduced by 30–40%. The results obtained with intravenous BPs are generally viewed as better than those obtained with oral clodronate. However, preference can be given to the oral route when BPs are started early in the process of metastatic bone disease in a patient receiving hormone therapy. According to the recently published ASCO guidelines, pamidronate 90 mg i.v. delivered over 2 h every 3–4 weeks can be recommended in patients with metastatic breast cancer who have imaging evidence of lytic destruction of bone and who are concurrently receiving systemic therapy with hormonal therapy or chemotherapy. Furthermore, the ASCO Panel considered it "reasonable" to start i.v. BPs in women with localized pain whose bone scans were abnormal and plain radiographs normal, but not when an abnormal bone scan is asymptomatic. The pertinence of these criteria is discussed below. Because BPs are providing supportive care, reducing the rate of skeletal morbidity but evidently not abolishing it, the criteria for stopping their administration have to be different from those used for classic antineoplastic drugs, and they should not be stopped when metastatic bone disease is progressing. However, criteria to determine whether and for how long an individual patient benefits from their administration are lacking. New biochemical markers of bone resorption might help identify those patients continuing to benefit from therapy. Even better results have been achieved in patients with multiple myeloma, and the general consensus is that BPs should be started as soon as the diagnosis of lytic disease is made in myeloma patients. On the other hand, data are scanty in prostate cancer, but large-scale trials with potent BPs are ongoing or planned in such patients. Similar results to those achieved with pamidronate have been obtained with monthly 6-mg infusions of the newer BP ibandronate in patients with breast cancer metastatic to bone. The tolerance of ibandronate could be better, and the drug has the potential to be administered as a 15- to 30-min infusion. Zoledronate can also be administered safely as a 15-min 4-mg infusion, and large scale phase III trials have just been completed. These newer BPs will simplify the current therapeutic schemes and improve the cost-effectiveness ratio; they also have the potential to improve the therapeutic efficacy, at least in patients with an aggressive osteolytic disease or when given as adjuvant therapy. For that matter, initial data with clodronate indicate that they have the potential to prevent the development of bone metastases, but the use of BPs in the adjuvant setting must still be viewed as experimental.
         datePublished:2001-10-19T00:00:00Z
         dateModified:2001-10-19T00:00:00Z
         pageStart:399
         pageEnd:407
         sameAs:https://doi.org/10.1007/s005200100292
         keywords:
            Bone metastases Osteolysis Bisphosphonates Breast cancer Myeloma
            Oncology
            Nursing
            Nursing Research
            Pain Medicine
            Rehabilitation Medicine
         image:
         isPartOf:
            name:Supportive Care in Cancer
            issn:
               1433-7339
               0941-4355
            volumeNumber:10
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:J. Body
               affiliation:
                     name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
                     address:
                        name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:I. Mancini
               affiliation:
                     name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
                     address:
                        name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Bisphosphonates for cancer patients: why, how, and when?
      description:Bisphosphonates (BPs) are potent inhibitors of osteoclast-mediated bone resorption, and it is well accepted that tumor cells in bone, especially breast cancer and myeloma cells, can stimulate osteoclast formation and activity leading to the release of growth factors or cytokines, which will further stimulate cancer cells' growth and their secretion of osteolytic factors. BPs are now the standard treatment for cancer hypercalcemia, for which a dose of 90 mg of pamidronate or 1500 mg of clodronate is recommended; the former compound is more potent and has a longer lasting effect. Repeated pamidronate infusions exert clinically relevant analgesic effects in more than half of patients with metastatic bone pain. Recent data suggest that non-responding patients should perhaps be treated with higher doses. The optimal dose actually remains to be defined, especially as it is thought that it is probably a function of the disease stage. Regular pamidronate infusions can also achieve a partial objective response according to conventional UICC criteria and they can almost double the objective response rate to chemotherapy. Lifelong administration of oral clodronate to patients with breast cancer metastatic to bone reduces the frequency of morbid skeletal events by more than one-fourth. Two double-blind randomized placebo-controlled trials comparing monthly 90 mg pamidronate infusions to placebo infusions for 1–2 years in addition to hormone or chemotherapy in patients with at least one lytic bone metastasis have shown that the mean skeletal morbidity rate could be reduced by 30–40%. The results obtained with intravenous BPs are generally viewed as better than those obtained with oral clodronate. However, preference can be given to the oral route when BPs are started early in the process of metastatic bone disease in a patient receiving hormone therapy. According to the recently published ASCO guidelines, pamidronate 90 mg i.v. delivered over 2 h every 3–4 weeks can be recommended in patients with metastatic breast cancer who have imaging evidence of lytic destruction of bone and who are concurrently receiving systemic therapy with hormonal therapy or chemotherapy. Furthermore, the ASCO Panel considered it "reasonable" to start i.v. BPs in women with localized pain whose bone scans were abnormal and plain radiographs normal, but not when an abnormal bone scan is asymptomatic. The pertinence of these criteria is discussed below. Because BPs are providing supportive care, reducing the rate of skeletal morbidity but evidently not abolishing it, the criteria for stopping their administration have to be different from those used for classic antineoplastic drugs, and they should not be stopped when metastatic bone disease is progressing. However, criteria to determine whether and for how long an individual patient benefits from their administration are lacking. New biochemical markers of bone resorption might help identify those patients continuing to benefit from therapy. Even better results have been achieved in patients with multiple myeloma, and the general consensus is that BPs should be started as soon as the diagnosis of lytic disease is made in myeloma patients. On the other hand, data are scanty in prostate cancer, but large-scale trials with potent BPs are ongoing or planned in such patients. Similar results to those achieved with pamidronate have been obtained with monthly 6-mg infusions of the newer BP ibandronate in patients with breast cancer metastatic to bone. The tolerance of ibandronate could be better, and the drug has the potential to be administered as a 15- to 30-min infusion. Zoledronate can also be administered safely as a 15-min 4-mg infusion, and large scale phase III trials have just been completed. These newer BPs will simplify the current therapeutic schemes and improve the cost-effectiveness ratio; they also have the potential to improve the therapeutic efficacy, at least in patients with an aggressive osteolytic disease or when given as adjuvant therapy. For that matter, initial data with clodronate indicate that they have the potential to prevent the development of bone metastases, but the use of BPs in the adjuvant setting must still be viewed as experimental.
      datePublished:2001-10-19T00:00:00Z
      dateModified:2001-10-19T00:00:00Z
      pageStart:399
      pageEnd:407
      sameAs:https://doi.org/10.1007/s005200100292
      keywords:
         Bone metastases Osteolysis Bisphosphonates Breast cancer Myeloma
         Oncology
         Nursing
         Nursing Research
         Pain Medicine
         Rehabilitation Medicine
      image:
      isPartOf:
         name:Supportive Care in Cancer
         issn:
            1433-7339
            0941-4355
         volumeNumber:10
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:J. Body
            affiliation:
                  name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
                  address:
                     name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:I. Mancini
            affiliation:
                  name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
                  address:
                     name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Supportive Care in Cancer
      issn:
         1433-7339
         0941-4355
      volumeNumber:10
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
      address:
         name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
         type:PostalAddress
      name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
      address:
         name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:J. Body
      affiliation:
            name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
            address:
               name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
               type:PostalAddress
            type:Organization
      name:I. Mancini
      affiliation:
            name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
            address:
               name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
      name:Supportive Care Clinic and Clinic of Endocrinology/Bone Diseases, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(27)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.9s.

LINK . SPRINGER . COM {}